PDF电子书：Therapeutic Oligonucleotides (Springer MMB-V764, 2011).pdf

xyklmu

* b1 n5 |3 X6 V- N. S( ]- r3 _9 Y4 y
[hide][/hide]
+ ?$ {" f; Q0 R3 U# N+ TTherapeutic Oligonucleotides7 U+ L9 Z; Y9 g& K4 t: S! l5 U
Methods and Protocols   Springer MMB-V764, 2011     
% q, D4 c  P* ^$ _$ `) AEdited by
" P) }! n0 k0 C$ tJohn Goodchild
8 D* J2 l- h' I7 fDepartment of Chemistry, Worcester State University,Worcester, MA, USA
3 X% w) b8 |. R2 z6 D7 r( n' f
4 t$ a/ r- h: m0 z* ]Contents( s& r* e0 t( l4 Q) {' h
Preface . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . v
* g1 g1 A5 V: r$ K& G" b' e1 L+ RContributors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ix
; K) R& e( ~& t; G* O( u% }1. Therapeutic Oligonucleotides . . . . . . . . . . . . . . . . . . . . . . . . . . . 1" m  R: x4 l6 _2 V+ {9 {9 I
John Goodchild
* M* X9 O* d7 E; d$ j, E/ y7 W! y2. Dinucleotides Containing 3-S-Phosphorothiolate Linkages . . . . . . . . . . . . 17
3 c4 ~. r% l" @+ C8 y' YJames W. Gaynor and Richard Cosstick
- z9 a& F- j9 h; s  ^5 h$ G3. 2-O,4-C-Methyleneoxymethylene Bridged Nucleic Acids (2,4-BNACOC) . . . . 31& B5 ~7 f7 v0 P5 m. B0 k
Yoshiyuki Hari, Tetsuya Kodama, Takeshi Imanishi,! t$ o& K7 {6 h" c! n
and Satoshi Obika4 w6 h/ I% z6 C" ]
4. A Non-covalent Peptide-Based Strategy for Ex Vivo and In Vivo: q: I7 W% I7 f% o: \, N% v7 O( {5 q
Oligonucleotide Delivery . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
% n; \3 O: [' }6 K5 [8 `. ^4 L7 bLaurence Crombez, May C. Morris, Frederic Heitz, and Gilles Divita
: o$ o4 l# m  N% `' L5. Cell-Penetrating Peptides-Based Strategies for the Delivery of Splice
& i: O, o9 ~; j* TRedirecting Antisense Oligonucleotides . . . . . . . . . . . . . . . . . . . . . . 75
* D1 s  z7 K: CSamir El Andaloussi, Fatouma Said Hassane, Prisca Boisguerin,
7 F, E8 j, D% e: d3 ORannar Sillard, Ülo Langel, and Bernard Lebleu& g* R5 x  I* d/ i
6. A Nanoparticle for Tumor Targeted Delivery of Oligomers . . . . . . . . . . . . 91
% \6 J$ _  z$ q" _5 z3 qXinrong Liu, Yi Wang, and Donald J. Hnatowich) b: j# g; y3 Q5 l
7. Light-Directed Delivery of Nucleic Acids . . . . . . . . . . . . . . . . . . . . . 107
5 @0 b$ U8 X# {2 r# qSigurd Bøe, Lina Prasmickaite, Birgit Engesæter, and Eivind Hovig
0 |- S, l: I. l, k& k8. Antibody Targeted siRNA Delivery . . . . . . . . . . . . . . . . . . . . . . . . 123* b1 B8 m5 d( r7 j( w; i
Masoud M. Toloue and Lance P. Ford4 z' W9 |: q2 X
9. Aptamer–Drug Conjugation for Targeted Tumor Cell Therapy . . . . . . . . . . 141
6 E3 A3 g  A; Q' J* G, ~Michael J. Donovan, Ling Meng, Tao Chen, Yunfei Zhang,
- z' y+ ], N% CKwame Sefah, and Weihong Tan$ n8 P' p: D# }; L
10. Five-Step Process for Screening Antisense Compounds for Efficacy: Gene
+ P7 l( r# Y5 ~0 I( |Target IL-12Rb2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 153' t  V4 s/ e! D' m. ^2 N
Nikki B. Marshall, Laura L. Hauck, and Dan V. Mourich0 B; {. j( ], g  s
11. Diverse Small Non-coding RNAs in RNA Interference Pathways . . . . . . . . . 169- X+ _9 |  G' Q) \9 L3 q: }/ V
Liande Li and Yi Liu
6 A7 w# d8 ?9 g- }8 o+ `4 N12. Quantification of siRNAs In Vitro and In Vivo . . . . . . . . . . . . . . . . . . . 183& ~! ?7 w5 ^8 G7 x
Angie Cheng, Alexander V. Vlassov, and Susan Magdaleno7 ^6 L1 b' L1 }- O
vii
: P: ]- _& S) E4 D6 Wviii Contents( o* n0 |' J" _; i8 N, @9 _. J8 F
13. Optimization of Transfection Conditions and Analysis of siRNA Potency- Y7 |& h" H* @3 a+ C, ~
Using Real-time PCR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 199
0 g0 d1 Q- }% P$ x% K( KAngie Cheng, Susan Magdaleno, and Alexander V. Vlassov
6 @+ Q4 I( `0 i  R7 A14. siRNA Knockdown of Gene Expression in Endothelial Cells . . . . . . . . . . . . 215, o* F8 @* h% G- Z' J
Emily Dennstedt and Brad Bryan) M1 k+ f: X1 V
15. Using RNA Interference in Schistosoma mansoni . . . . . . . . . . . . . . . . . . 2239 [9 q" I, D. S# K) h# [* X
Rita Bhardwaj, Greice Krautz-Peterson, and Patrick J. Skelly. M% m8 J9 L9 }  z; f
16. Performing the Labeled microRNA Pull-Down (LAMP) Assay System:9 B5 S5 W" c9 {
An Experimental Approach for High-Throughput Identification of
6 v5 s) }9 R% e; pmicroRNA-Target mRNAs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 241
+ T7 w, s8 J: j. ?Ren-Jun Hsu and Huai-Jen Tsai' A3 T. e$ _, m
17. Synthesis, Purification, and Characterization of Oligoribonucleotides that
/ e) J* B: t2 C: Z& V. b7 `Act as Agonists of TLR7 and/or TLR8 . . . . . . . . . . . . . . . . . . . . . . 249
2 }! `9 U) c6 P8 |$ z7 uTao Lan and Ekambar R. Kandimalla
$ |3 I7 T8 T! l. v4 l, P. J0 W18. Synthesis, Purification, and Characterization of Immune-Modulatory
, n$ M3 `* J2 w) ~Oligodeoxynucleotides that Act as Agonists of Toll-Like Receptor 9 . . . . . . . . 263
' \. R! M% [5 R, {. R2 U& wMallikarjuna Reddy Putta, Dong Yu, and Ekambar R. Kandimalla& o" s1 Q  P8 c! l! Z
19. Surface Plasmon Resonance Investigation of RNA Aptamer–RNA Ligand
+ j1 ]6 `- j0 W9 ?2 r% ~Interactions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 279
! z. U2 J9 G% R; k6 E- u" xCarmelo Di Primo, Eric Dausse, and Jean-Jacques Toulmé* J, j% [8 M- D9 b. p, p$ M* T
20. Practical Considerations for Analyzing Antigene RNAs (agRNAs): RNA; m. _3 p$ [/ }3 i7 o
Immunoprecipitation of Argonaute Protein . . . . . . . . . . . . . . . . . . . . 3018 [* ?' j/ J0 M# E  `
Jacob C. Schwartz and David R. Corey4 o* A2 _; L+ B3 j5 d. D
21. Inhibition of Human Papillomavirus Expression Using DNAzymes . . . . . . . . 317. a0 W9 Z! k& T% v
María Luisa Benítez-Hess, Pablo Reyes-Gutiérrez,
8 a4 A$ Y6 Z" R; n! c7 U- K& ~and Luis Marat Alvarez-Salas# e% h+ J! h- o, }' V- v
Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 337

hualin

ziyumo

nice

bluesuns

呵呵 高高实在是高~~~~~  

dypnr

谢谢分享了!  

sky蓝

勤奋真能造就财富吗？  

foxok

慢慢来，呵呵  

石头111

呵呵 大家好奇嘛 来观看下~~~~  

罗马星空

我起来了 哈哈 刚才迷了会  

科研人

我的啦嘿嘿